Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Microsystem Reduces Cost of Developing Ion Channel Drugs

By BiotechDaily International staff writers
Posted on 11 Dec 2013
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
The use of a microsystem that generates ion channels in a cell-free medium is expected to boost development of drugs that target these channels in the treatment of diseases such as cystic fibrosis, myasthenia gravis, and epilepsy.

The effect of drugs on ion channels is currently studied by electrophysiology, which measures an electric current across ion channel proteins. This, however, is a slow and expensive process that is carried out using ion channels in living cell membranes.

In a paper published in the October 18, 2013, online edition of the journal Analyst, investigators at the University of Southampton (United Kingdom) in collaboration with colleagues at the University of Quebec (Montreal, Canada) described the development of a cell-free expression mixture that allows ion channels to be inserted into stable artificial "cell membranes."

Results of the study showed that single-channel current measurements of the potassium channels KcsA and hERGS5–S6 could be obtained by direct insertion in interdroplet lipid bilayers from microliters of a cell-free expression medium.

"By putting the ion channel into an artificial membrane, we only have one type of channel, no living cells, and a relatively inexpensive method for testing for several of these types of channels at once," said senior author Dr. Maurits de Planque, lecturer in electronics and computer science at the University of Southampton. "Researchers have experimented with cell-free mixtures before, but they found that this method was not economical due to the amount of expensive biochemicals required. Our proposal to develop a new platform, which uses a couple of microliters instead of milliliters, will be a very cost-effective way of doing this, particularly when the produced channel is directly inserted in a membrane for drug testing."

Related Links:

University of Southampton
University of Quebec



Channels

Genomics/Proteomics

view channel
Image: Nomarski interference contrast photomicrographs of Cryptosporidium in the feces of an HIV-positive human (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).

Advanced Genetic Tools Revamp Search for Drugs to Treat Cryptosporidium

Genetically engineered modifications to genome of the diarrhea-causing parasite Cryptosporidium are expected to expedite research towards vaccine and drug development to prevent or cure infection by this pathogen.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.